RayKnowChina Research Map
Shortlist

ShenzhenPeking University Health Science Center

Peking University Shenzhen Hospital

北京大学深圳医院

Listed for 18 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Peking University Shenzhen Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌8 papers led
  2. Hepatocellular carcinoma肝细胞癌22 papers led
  3. Stomach cancer胃癌8 papers led
  4. Chordoma脊索瘤0 papers led
  5. Osteosarcoma骨肉瘤2 papers led
  6. Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
  7. Neuroblastoma神经母细胞瘤1 paper led
  8. Multiple myeloma多发性骨髓瘤1 paper led
  9. Beta thalassaemiaβ 地中海贫血1 paper led
  10. Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征1 paper led
  11. IgG4-related diseaseIgG4相关性疾病2 papers led
  12. Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
  13. Spinal muscular atrophy脊髓性肌萎缩症0 papers led
  14. Fabry disease法布雷病0 papers led
  15. Alport syndromeAlport 综合征2 papers led
  16. IgA nephropathyIgA 肾病1 paper led
  17. Osteogenesis imperfecta成骨不全症1 paper led
  18. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led

Not listed for: Oesophageal squamous cell carcinoma, Hepatoblastoma, Retinoblastoma, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Haemophilia A, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Gaucher disease, Niemann–Pick disease type C, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 8 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 3320212022: 3320222023: 1120232024: 0020242025: 112025

8 hospitals in Shenzhen for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06301165

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesDongguan, Foshan, Guangzhou, Shenzhen, Wuhan

  2. Recruiting
    A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis
    Phase
    Not given
    Started
    2024-04
    Registry
    NCT06308328

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang Hospital; 9 listed hospitals as study sitesChengdu, Guangzhou, Shanghai, Shaoguan, Shenzhen, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEBV & screeningRecurrent / metastatic diseaseRadiotherapy technique
Departments in papersPathology / laboratory medicineMedical oncologyENT / head & neck surgeryNeurology

Over half of these papers are lab or animal studies.

Papers it led8
  1. A three-miRNA panel in serum: Serving as a novel diagnostic method for nasopharyngeal carcinoma.2025The International journal of biological markers
  2. Comprehensive single-cell transcriptomic and proteomic analysis reveals NK cell exhaustion and unique tumor cell evolutionary trajectory in non-keratinizing nasopharyngeal carcinoma.2023Journal of translational medicineFree full text
  3. Identification of DNA aptamers that specifically targets EBV+ nasopharyngeal carcinoma via binding with EphA2/CD98hc complex.2022Biochemical and biophysical research communications
  4. A panel of three serum microRNA can be used as potential diagnostic biomarkers for nasopharyngeal carcinoma.2022Journal of clinical laboratory analysisFree full text
  5. The Highly Expressed IFIT1 in Nasopharyngeal Carcinoma Enhances Proliferation, Migration, and Invasion of Nasopharyngeal Carcinoma Cells.2022Molecular biotechnology
  6. Long-term recurrence and brain metastasis of nasopharyngeal carcinoma mimicking cystic radiation encephalopathy relapse: a case report.2021BMC neurologyFree full text
  7. Transcriptomic Analyses Reveal Gene Expression Profiles and Networks in Nasopharyngeal Carcinoma.2021BioMed research internationalFree full text
  8. DVH Prediction for VMAT in NPC with GRU-RNN: An Improved Method by Considering Biological Effects.2021BioMed research internationalFree full text
All its trials on ClinicalTrials.gov, any status3
  1. A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal MucositisRecruitingNCT06308328Study siteStart 2024-04
  2. TPC Versus GP Induction Chemotherapy for Nasopharyngeal CarcinomaRecruitingNCT06301165Study sitePhase 2Start 2024-03
  3. To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal CancerStatus unknownNCT05198531Study sitePhase 1/Phase 2Start 2022-01
More papers found outside PubMed (not counted)4
  1. Small Molecule G07 Exhibits Dual Effects on Cell Motility by Enhancing Skin Wound Healing and Inhibiting Nasopharyngeal Carcinoma Metastasis2025International Journal of Radiation Oncology*Biology*Physicsarticle
  2. Additional file 1 of Comprehensive single-cell transcriptomic and proteomic analysis reveals NK cell exhaustion and unique tumor cell evolutionary trajectory in non-keratinizing nasopharyngeal carcinoma2023Figsharedataset
  3. Additional file 3 of Comprehensive single-cell transcriptomic and proteomic analysis reveals NK cell exhaustion and unique tumor cell evolutionary trajectory in non-keratinizing nasopharyngeal carcinoma2023Figsharedataset
  4. Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma2022Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 22 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
22
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 3320212022: 5520222023: 4420232024: 3320242025: 772025

8 hospitals in Shenzhen for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Registry
    NCT07500220

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  2. Recruiting
    Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Registry
    NCT07523529

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs
Departments in papersSurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicineRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led22
  1. Membranous Staining of CD10 Is Related to Steatosis Changes in Hepatocellular Carcinoma: An Investigation of CD10 Stainning in Hepatocellular Carcinoma, Focal Nodular Hyperplasia, and Intrahepatic Cholangiocarcinoma.2025Applied immunohistochemistry & molecular morphology : AIMM
  2. High expression of SMPD4 promotes liver cancer and is associated with poor prognosis.2025BMC research notesFree full text
  3. Prognostic implication of six m6A-modulated genes signature in the ferroptosis for hepatocellular carcinoma patients.2025Clinical and experimental medicineFree full text
  4. LONP1 Promotes Hepatocarcinogenesis by Degrading ACO2 to Alleviate Ferroptosis.2025Frontiers in bioscience (Landmark edition)
  5. Deciphering Epigenetic and Post-Translational Modifications in Ferroptosis: A Scientometric and Visualization Study.2025International journal of medical sciencesFree full text
  6. Plasma lipidomic analysis reveals disruption of ether phosphatidylcholine biosynthesis and facilitates early detection of hepatitis B-related hepatocellular carcinoma.2025Lipids in health and diseaseFree full text
  7. ADARp110 promotes hepatocellular carcinoma progression via stabilization of CD24 mRNA.2025Proceedings of the National Academy of Sciences of the United States of AmericaFree full text
  8. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.2024Apoptosis : an international journal on programmed cell death
  9. Predictive value of a stemness-based classifier for prognosis and immunotherapy response of hepatocellular carcinoma based on bioinformatics and machine-learning strategies.2024Frontiers in immunologyFree full text
  10. Targeting ferroptosis in hepatocellular carcinoma.2024Hepatology international
  11. Silencing of TMED5 inhibits proliferation, migration and invasion, and enhances apoptosis of hepatocellular carcinoma cells.2023Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  12. A novel hepatocellular carcinoma-specific mTORC1-related signature for anticipating prognosis and immunotherapy.2023AgingFree full text
  13. Bispecific GPC3/PD‑1 CAR‑T cells for the treatment of HCC.2023International journal of oncologyFree full text
  14. MAT1A Suppression by the CTBP1/HDAC1/HDAC2 Transcriptional Complex Induces Immune Escape and Reduces Ferroptosis in Hepatocellular Carcinoma.2023Laboratory investigation; a journal of technical methods and pathology
  15. MicroRNA-139-5p negatively regulates NME1 expression in hepatocellular carcinoma cells.2022Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  16. LINC02362 attenuates hepatocellular carcinoma progression through the miR-516b-5p/SOSC2 axis.2022AgingFree full text
  17. Identification and validation of a fatty acid metabolism-related lncRNA signature as a predictor for prognosis and immunotherapy in patients with liver cancer.2022BMC cancerFree full text
  18. microRNA-378a-3p regulates the progression of hepatocellular carcinoma by regulating PD-L1 and STAT3.2022BioengineeredFree full text
  19. Objective to identify and verify the regulatory mechanism of DTNBP1 as a prognostic marker for hepatocellular carcinoma.2022Scientific reportsFree full text
  20. Angiotensin II promotes EMT of hepatocellular carcinoma cells through high mobility group protein B1 mediated by E4F1.2021Biochemical and biophysical research communications
  21. Identification of Biomarkers Related to Immune Cell Infiltration in Hepatocellular Carcinoma Using Gene Co-Expression Network.2021Pathology oncology research : PORFree full text
  22. Noninvasive Detection of Hepatocellular Carcinoma with Circulating Tumor DNA Features and α-Fetoprotein.2021The Journal of molecular diagnostics : JMD
Chinese-language papers (not in the count)1
  1. [Research progress on ferroptosis regulation in tumor immunity of hepatocellular carcinoma].2024Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciencesFree full text
All its trials on ClinicalTrials.gov, any status4
  1. Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCCRecruitingNCT07500220Study sitePhase 1/Phase 2Start 2026-03
  2. Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid TumorsRecruitingNCT07523529Study sitePhase 1/Phase 2Start 2026-03
  3. Study of BGB-A317 in Participants With Previously Treated Unresectable HCCCompletedNCT03419897Study sitePhase 2Start 2018-04
  4. The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma SubjectsTerminatedNCT03236649Study sitePhase 3Start 2017-09

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 8 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.08%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 2220242025: 112025

7 hospitals in Shenzhen for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Registry
    NCT07523529

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  2. Recruiting
    Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Registry
    NCT07551362

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesChemotherapy & combined treatmentImmunotherapy & targeted drugsImaging & AI
Departments in papersMedical oncology

Over half of these papers are lab or animal studies.

Papers it led8
  1. The IL-17 axis in gastric carcinogenesis: From inflammation to oncogenic transformation.2026Cytokine & growth factor reviews
  2. Single-cell multi-omics analysis reveals the plasticity of isthmus stem cells in gastric carcinogenesis.2025Computers in biology and medicine
  3. PDLIM1 interacts with HK2 to promote gastric cancer progression through enhancing the Warburg effect via Wnt/β-catenin signaling.2024Cell and tissue research
  4. Prognostic value of inflammatory and nutritional indexes among patients with unresectable advanced gastric cancer receiving immune checkpoint inhibitors combined with chemotherapy-a retrospective study.2024PeerJFree full text
  5. FTO Promotes the Stemness of Gastric Cancer Cells.2023DNA and cell biology
  6. Immune activity score to assess the prognosis, immunotherapy and chemotherapy response in gastric cancer and experimental validation.2023PeerJFree full text
  7. HIF in Gastric Cancer: Regulation and Therapeutic Target.2022Molecules (Basel, Switzerland)Free full text
  8. Mutations in ALK and TSC1 in a gastrointestinal stromal tumor: a case report.2021BMC surgeryFree full text
All its trials on ClinicalTrials.gov, any status9
  1. Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid TumorsRecruitingNCT07523529Study sitePhase 1/Phase 2Start 2026-03
  2. Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ CancerRecruitingNCT07551362Study sitePhase 1/Phase 2Start 2026-03
  3. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  4. Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer TrialStatus unknownNCT04744649Study sitePhase 2Start 2021-03
  5. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell InjectionActive, not recruitingNCT04581473Study sitePhase 1/Phase 2Start 2020-10
  6. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  7. A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric CancerStatus unknownNCT04139135Study sitePhase 3Start 2019-12
  8. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)CompletedNCT03675737Study sitePhase 3Start 2018-11
  9. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China ExtensionWithdrawnNCT04859582Study sitePhase 3Start 2018-11

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led no English-language PubMed papers on chordoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Shenzhen for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 2 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

23 hospitals in Shenzhen for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

4 hospitals in Shenzhen for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

10 hospitals in Shenzhen for neuroblastoma352 hospitals in China for neuroblastoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Registry
    NCT07502287

    Age 12 months to 21 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 1 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.06%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
5
led by another institution

5 hospitals in Shenzhen for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  2. Recruiting
    A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07518186

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Hangzhou, Nanchang, Nanjing, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an

  3. Recruiting
    Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Registry
    NCT07523555

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  4. Recruiting
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 3
    Started
    2022-10
    Registry
    NCT05552222

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  5. Recruiting
    BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
    Phase
    Phase 1
    Started
    2019-07
    Registry
    NCT04162353

    Age not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesBispecific & antibody drugs
Departments in papersPathology / laboratory medicine
Papers it led1
  1. Rapid identification and quantification of residual daratumumab in multiple myeloma patients by MALDI - TOF mass spectrometry.2026Clinica chimica acta; international journal of clinical chemistry
All its trials on ClinicalTrials.gov, any status9
  1. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07518186Study sitePhase 3Start 2026-05
  2. Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic MalignanciesRecruitingNCT07523555Study sitePhase 1/Phase 2Start 2026-03
  3. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  4. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10
  5. BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid LymphomaRecruitingNCT04162353Study sitePhase 1Start 2019-07
  6. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive, not recruitingNCT06208150Study sitePhase 3Start 2024-01
  7. A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to TreatmentActive, not recruitingNCT05455320Study sitePhase 3Start 2022-10
  8. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05083169Study sitePhase 3Start 2021-10
  9. BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple MyelomaStatus unknownNCT04156269Study siteEarly phase 1Start 2018-08

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 1 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

7 hospitals in Shenzhen for beta thalassaemia157 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine
Papers it led1
  1. Mutational spectrum of HBD gene in the Chinese population: Description of 36 mutations including 11 novel variants.2023International journal of laboratory hematology
Chinese-language papers (not in the count)1
  1. [Research progress on differential diagnosis of thalassemia trait and iron deficiency anemia by blood erythrocyte parameters].2024Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]

Run the PubMed searchClinicalTrials.gov

Blood disorders

Atypical haemolytic uraemic syndrome

非典型溶血性尿毒症综合征

Led 1 of the 27 English-language PubMed papers on atypical haemolytic uraemic syndrome with an author in mainland China, 2021–2025: 3.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Shenzhen for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome

No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led 2 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

2 hospitals in Shenzhen for IgG4-related disease46 hospitals in China for IgG4-related disease

No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesKidney, retroperitoneum & vesselsDiagnosis & look-alikes
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

7 hospitals in Shenzhen for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Ibrutinib Delays ALS Installation and Increases Survival of SOD1G93A Mice by Modulating PI3K/mTOR/Akt Signaling.2023Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology

Run the PubMed searchClinicalTrials.gov

Other diseases

Spinal muscular atrophy

脊髓性肌萎缩症

Led no English-language PubMed papers on spinal muscular atrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Shenzhen for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy

No open trial on spinal muscular atrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Adult Spinal Muscular Atrophy (SMA) China RegistryActive, not recruitingNCT05618379Study siteStart 2023-01

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Shenzhen for Fabry disease85 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology
Chinese-language papers (not in the count)1
  1. [Clinical analysis of 10 patients with Fabry disease].2024Zhonghua nei ke za zhi

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led 2 of the 58 English-language PubMed papers on Alport syndrome with an author in mainland China, 2021–2025: 3.5%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

4 hospitals in Shenzhen for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

10 hospitals in Shenzhen for IgA nephropathy346 hospitals in China for IgA nephropathy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
    Phase
    Phase 3
    Started
    2025-07
    Registry
    NCT06963827

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBaotou, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Ningbo, Shanghai, Shenzhen, Wuxi, Xiamen, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPathology / laboratory medicine
Papers it led1
  1. Serum human epididymis protein 4 is associated with disease severity in patients with IgA nephropathy.2024Clinical biochemistry
All its trials on ClinicalTrials.gov, any status5
  1. A Study of Mezagitamab in Adults With Kidney Condition Called IgA NephropathyRecruitingNCT06963827Study sitePhase 3Start 2025-07
  2. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  3. TESTING -ON Post-Trial ObservatioNal Cohort StudyCompletedNCT05434325Study siteStart 2022-12
  4. Atrasentan in Patients With IgA NephropathyActive, not recruitingNCT04573478Study sitePhase 3Start 2020-12
  5. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)CompletedNCT01560052Study siteN/AStart 2012-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led 1 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

4 hospitals in Shenzhen for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

3 hospitals in Shenzhen for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07282353

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCARecruitingNCT07282353Study sitePhase 3Start 2025-12

Run the PubMed searchClinicalTrials.gov

Other linked evidence

Getting in touch

Name card to show staff or a driver

北京大学深圳医院

Peking University Shenzhen Hospital

深圳

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Peking University Shenzhen Graduate School; Shenzhen Hospital; Shenzhen Hospital of Peking University; Shenzhen Hospital of Peking Univeristy; Peking University shenzhen hospital; Shenzhen Central Hospital

Suggest a correctionDownload the data